Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Revenue of Outlook Therapeutics, Inc. (OTLK)
Revenue in 2023 (TTM): $
According to Outlook Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Outlook Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-44,188 | $-57,375,932 | $-58,979,868 | $-58,982,668 |
| 2022 | $ | $-204,694 | $-62,866,059 | $-66,049,464 | $-66,052,264 |
| 2021 | $ | $-262,139 | $-51,464,595 | $-53,161,000 | $-53,163,000 |
| 2020 | $ | $-554,069 | $-35,758,944 | $-38,511,000 | $-35,239,000 |
| 2019 | $8.15 M | $8.12 M | $-31,106,227 | $-37,934,788 | $-34,523,787 |
| 2018 | $3.09 M | $3.07 M | $-26,794,575 | $-33,740,177 | $-46,114,924 |
| 2017 | $3.81 M | $3.79 M | $-30,029,694 | $-38,347,627 | $-38,849,127 |
| 2016 | $2.98 M | $2.95 M | $-48,952,896 | $-53,226,262 | $-53,329,262 |
| 2015 | $5.22 M | $5.18 M | $-44,738,026 | $-48,859,965 | $-47,393,283 |
| 2014 | $9.05 M | $9.04 M | $-11,513,926 | $-13,293,455 | $-13,732,473 |